Valanafusp Biosimilar – Anti-INSR mAb – Research Grade from ProteoGenix; catalogue PX-TA1734; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Valanafusp Biosimilar is a novel therapeutic antibody that targets the insulin receptor (INSR). It is a monoclonal antibody (mAb) that has been developed as a biosimilar to the existing anti-INSR mAbs. This biosimilar has been designed to mimic the structure and function of the original anti-INSR mAb, while also providing improved efficacy and safety profiles.
Valanafusp Biosimilar is a humanized IgG1 monoclonal antibody that has been engineered to specifically target the INSR. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions are responsible for binding to the INSR, while the constant regions provide effector functions such as complement activation and antibody-dependent cellular cytotoxicity.
The amino acid sequence of Valanafusp Biosimilar has been carefully selected to closely resemble that of the original anti-INSR mAb. This ensures that the biosimilar retains the same binding affinity and specificity for the INSR, while also minimizing the risk of immunogenicity.
Valanafusp Biosimilar exerts its therapeutic activity by binding to the INSR and blocking its activity. The INSR is a transmembrane receptor that plays a crucial role in the regulation of glucose metabolism and growth. Dysregulation of the INSR has been implicated in various diseases, including diabetes and cancer.
By binding to the INSR, Valanafusp Biosimilar prevents the activation of downstream signaling pathways that are involved in glucose uptake and cell growth. This leads to a decrease in blood glucose levels and inhibition of tumor growth.
Valanafusp Biosimilar has potential applications in the treatment of both diabetes and cancer. In diabetes, it can be used to improve glycemic control by reducing insulin resistance and promoting glucose uptake. This can lead to better management of blood glucose levels and prevention of long-term complications associated with diabetes.
In cancer, Valanafusp Biosimilar can be used as a targeted therapy to inhibit the growth and proliferation of cancer cells. By blocking the activity of the INSR, it can prevent the growth and spread of tumors, while also enhancing the effects of other cancer treatments such as chemotherapy.
Valanafusp Biosimilar is also available in a research grade form for use in laboratory studies and pre-clinical research. This grade of the biosimilar is produced using the same manufacturing process as the clinical grade, but is not intended for human use.
The research grade Valanafusp Biosimilar can be used to study the mechanism of action of the biosimilar, as well as its potential therapeutic effects in various disease models. It can also be used to compare the efficacy and safety of the biosimilar with other anti-INSR mAbs.
In summary, Valanafusp Biosimilar is a novel therapeutic antibody that targets the INSR. It has a similar structure and activity to the original anti-INSR mAb, but with improved efficacy and safety profiles. This biosimilar has potential applications in the treatment of diabetes and cancer, and is also available in a research grade form for use in laboratory studies. Further research and clinical trials are needed to fully evaluate the potential of Valanafusp Biosimilar as a therapeutic option for these diseases.
ProteoGenix catalogue number PX-TA1734. For research use only.
Target: Valanafusp Biosimilar – Anti-INSR mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Valanafusp Biosimilar – Anti-INSR mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
